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ABSTRACT 25 
HIV-1 replication requires direct interaction between HIV-1 reverse transcriptase (RT) and 26 
cellular eukaryotic translation elongation factor 1A (eEF1A). Our previous work showed that 27 
disrupting this interaction inhibited HIV-1 uncoating, reverse transcription and replication, 28 
indicating its potential as an anti-HIV-1 target. Here we develop a sensitive, live-cell split 29 
luciferase complementation assay (NanoBiT) to quantitatively measure inhibition of HIV-1 RT 30 
interacting with eEF1A. We used this to screen a small molecule library and discovered small 31 
molecule oxazole-benzenesulfonamides (C7, C8, C9), which dose-dependently and specifically 32 
inhibited the HIV-1 RT interaction with eEF1A. These compounds directly bound to HIV-1 33 
RT in a dose-dependent manner, as assessed by a biolayer-interferometry (BLI) assay, but did 34 
not bind to eEF1A. These oxazole-benzenesulfonamides did not inhibit enzymatic activity of 35 
recombinant HIV-1 RT in a homopolymer assay, but did inhibit reverse transcription and 36 
infection of both wild type (WT) and NNRTI-resistant HIV-1 in a dose-dependent manner in 37 
HEK293T cells. Infection of HeLa cells was significantly inhibited by the oxazole-38 
benzenesulfonamides and the antiviral activity was most potent against replication stages 39 
before 8 h post-infection. In human primary activated CD4
+ 
T cells, C7 inhibited HIV-1 40 
infectivity and replication up to 6 days post-infection. The data suggest a novel mechanism of 41 
HIV-1 inhibition and further elucidate how the RT-eEF1A interaction is important for HIV-1 42 
replication. These compounds provide potential to develop a new class of anti-HIV-1 drugs to 43 
treat WT and NNRTI-resistant strains in people infected with HIV. 44 
IMPORTANCE 45 
Antiretroviral drugs protect many HIV-positive people, but their success can be compromised 46 
by drug resistant strains. To combat these strains, the development of new classes of HIV-1 47 
inhibitors is essential and a priority in the field. In this study we identified small molecules that 48 
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bind directly to HIV-1 reverse transcriptase (RT) and inhibit its interaction with cellular 49 
eEF1A, an interaction which we have previously identified as crucial for HIV-1 replication. 50 
These compounds inhibit intracellular HIV-1 reverse transcription and replication of WT HIV-51 
1, as well as HIV-1 mutants that are resistant to current RT inhibitors. A novel mechanism of 52 
action involving inhibition of the HIV-1 RT-eEF1A interaction is an important finding and a 53 
potential new way to combat drug-resistant HIV-1 strains in infected people. 54 
INTRODUCTION 55 
Human Immunodeficiency virus (HIV) is a member of the Retroviridae family and Lentivirus 56 
genus that infects and kills CD4
+
 T cells and can lead to acquired immune deficiency syndrome 57 
(AIDS). There are 37 million people living with HIV and there were one million AIDS-related 58 
deaths in 2017 (1). There are over 20 approved antiretroviral (ART) drugs and these are used in 59 
combination for maximal effectiveness and to minimise emergence of drug-resistant viral 60 
strains (2, 3). This treatment strategy is called combination antiretroviral therapy (cART) and 61 
has been highly successful for inhibiting HIV infection and preventing further transmission and 62 
progression to AIDS (4-6). However, HIV is able to rapidly mutate to become resistant to these 63 
antiretroviral drugs and is a major cause of progression to AIDS (3, 7, 8). Non-nucleoside 64 
reverse transcriptase inhibitors (NNRTIs) are the most affordable and widely used first-line 65 
antiviral drug treatment and these include the drugs nevirapine, efavirenez and delavirdine. By 66 
the end of 2016, NNRTI resistance levels were between 4% and 28% in people with 67 
suppressed viral load, and 47% to 90% in people with unsuppressed viral load (9). This 68 
highlights the need to further develop new classes of antiretroviral drugs with novel 69 
mechanisms of action to treat current and future drug-resistant HIV (10). 70 
Reverse transcription of HIV-1 is the conversion of the positive-sense single-stranded RNA 71 
genome into double-stranded DNA, which is a pre-condition for integration into the host 72 
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chromosomes for subsequent replication. This is primarily catalysed by the enzyme HIV-1 73 
reverse transcriptase (RT) as part of the reverse transcription complex (RTC), which contains 74 
several viral and host cell proteins (11). HIV-1 reverse transcriptase (RT) is a heterodimer 75 
composed of two related subunits, p66 and p51 (12-14). The p66 subunit contains the active 76 
sites for both DNA polymerase and RNase H activity, while p51 plays a structural role (12). 77 
Incoming deoxyribonucleotide triphosphates (dNTPs) bind at the polymerase active site and 78 
are polymerised to form double stranded DNA by reverse transcription. HIV RT is an effective 79 
target of antiretroviral drugs, and NNRTIs bind HIV RT and inhibit enzymatic activity to 80 
prevent reverse transcription (15). 81 
We were first to report that cellular factors were required for efficient reverse transcription (16-82 
18). We subsequently identified that eEF1A was important for reverse transcription and may be 83 
the predominant RT binding cellular protein in the RTC (19, 20). Mutations that reduce the 84 
RT-eEF1A interaction significantly impair HIV-1 replication in CD4
+
 T cells, highlighting the 85 
importance of this interaction in maintaining a stable RTC capable of completing reverse 86 
transcription (21). Using the eEF1A-binding compound didemnin B, proof of principle has 87 
been demonstrated that the RT-eEF1A complex is a druggable target for inhibiting HIV-1 88 
replication (20). However, clinical trials with didemnin B in cancer patients showed significant 89 
toxicity and side-effects (22, 23), likely because didemnin B binds eEF1A and inhibits 90 
translation, and therefore cannot be pursued as an HIV-1 treatment. Therefore, we 91 
hypothesised that RT-binding compounds that inhibit the interaction of RT with eEF1A would 92 
inhibit reverse transcription and HIV-1 replication with lower toxicity. Here, we evaluated a 93 
compound library and identified that oxazole-benzenesulfonamide derivatives bind RT (but not 94 
eEF1A) and inhibit both RT-eEF1A interaction and HIV-1 replication in cells. 95 
 96 
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RESULTS 97 
Establishing a live-cell NanoBiT assay for quantitating inhibition of the RT-eEF1A 98 
interaction for small molecule inhibitor screening 99 
Split-luciferase complementation (SLC) assays have been previously used as small molecule 100 
screening assays to identify inhibitors of protein-protein interactions (24, 25). NanoBiT 101 
(Promega) is a SLC assay where a NanoLuc luciferase signal is generated when the 17.6 kDa 102 
‘Large BiT’ (LgBiT) and 1.3 kDa ‘Small BiT’ (SmBiT) subunits of the enzyme come together 103 
to form a functional luciferase, triggered by the interaction of their respective fusion proteins 104 
(26). Here the HIV-1 RTp66 coding region was inserted at the N-terminus of LgBiT for 105 
expression of the RTp66-LgBiT fusion protein, and eEF1A was inserted at the N-terminus of 106 
SmBiT for expression of the eEF1A-SmBiT fusion protein. As a control protein-protein 107 
interaction, the Zika virus (ZIKV) NS2B gene was inserted at the C-terminus of LgBiT for 108 
expression of the LgBiT-NS2B fusion protein, and the protease domain of NS3 (NS3pro) was 109 
inserted at the N-terminus of SmBiT for expression of the NS3pro-SmBiT fusion protein. 110 
HEK293T cells were lysed 24 hrs after transfection of these expression vectors and lysates 111 
were analysed by western blot. This showed successful expression of RTp66-LgBiT (Fig 1A), 112 
eEF1A-SmBiT (Fig 1B), ZIKV NS3pro-SmBiT (Fig 1C), ZIKV LgBiT-NS2B (Fig 1D), and 113 
the HaloTag-SmBiT negative control (Fig 1B). LgBiT-NS2B and NS3pro-SmBiT were fused 114 
with FLAG and HA tags respectively for detection by western blot, but the untagged vectors 115 
were used in NanoBiT. HEK293T cells expressing RTp66-LgBiT co-transfected with eEF1A-116 
SmBiT produced a significantly higher NanoLuc luciferase signal than RTp66-LgBiT co-117 
transfected with HaloTag-SmBiT (p < 0.0001) (Fig 1E). Also, ZIKV LgBiT-NS2B co-118 
transfected with NS3pro-SmBiT produced a significantly higher NanoLuc luciferase signal 119 
than LgBiT-NS2B co-transfected with HaloTag-SmBiT (p <0.0001) (Fig 1F). This indicates 120 
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that a specific luciferase signal was produced as a result of the HIV-1 RT-eEF1A and the ZIKV 121 
NS2B-NS3pro interactions in cells. 122 
The ‘Open Collection Scaffolds’ library from Compounds Australia was screened using the 123 
NanoBiT system to identify compounds with inhibitory activity against the RT-eEF1A 124 
interaction. The library comprises 1226 different scaffolds, and each scaffold has more than 30 125 
members to enable screening of a small collection with ready access to compounds of related 126 
structure. One compound was selected at random from each of the 1226 scaffolds. Compounds 127 
were plated in 96 well plates in assay-ready format by Compounds Australia. HEK293T cells 128 
co-transfected with the NanoBiT LgBiT and SmBiT plasmids were then seeded into the plates 129 
containing the compounds to a final concentration of 25 µM after 6 hrs of transfection. Cells 130 
were incubated with compounds overnight and NanoLuc luciferase signal was measured in live 131 
cells, immediately followed by a MTS cell proliferation assay to measure cell viability. The 132 
initial screen of 1226 compounds identified 320 compounds that reduced the luciferase signal 133 
by at least 40% while maintaining more than 70% cell viability (Table 1). The most potent 168 134 
compounds were selected for a repeat experiment with the same criteria as the primary (non-135 
specific) screen but with an added specificity control. Four compounds in this specific screen 136 
inhibited the HIV-1 RT-eEF1A interaction more than 1.5 times compared to the control, giving 137 
an overall hit rate of 0.33% for compounds with specific inhibition out of the initial library of 138 
1226 compounds. All compounds within these four scaffolds were then sourced from the 139 
‘Open Collection Scaffolds’ library (150 compounds) to establish structure-activity 140 
relationships (SAR) for each scaffold. A NanoBiT screen of the compound scaffold derivatives 141 
resulted in 16 hits that were evaluated for concentration response dependence. Nine 142 
compounds, featuring two different scaffolds, dose-dependently and specifically inhibited the 143 
HIV-1 RT-eEF1A interaction and were evaluated in more detail. 144 
 145 
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Benzimidazole-pyrrolones and oxazole-benzenesulfonamides inhibit the RT-eEF1A 146 
interaction and HIV-1 infectivity  147 
The nine compounds identified from dose-response screening plus a negative control were 148 
denoted C1-C10 and are described in Table 2 in the methods section. C1, C2, C3, C4 and C5 149 
are benzimidazole-pyrrolones, sharing a common substructure of 5-amino-4-(1H-150 
benzo[d]imidazol-2-yl)-1-phenyl-1,2-dihydro-3H-pyrrol-3-one. C6, C7 C8, C9 and C10 are 151 
oxazole-benzenesulfonamides, sharing the common substructure of 4-(oxazol-5-152 
yl)benzenesulfonamide. These compounds were serial diluted 2-fold from 25 µM to 0.195 µM 153 
and incubated with HEK293T cells, expressing either HIV-1 RTp66-LgBiT and eEF1A-154 
SmBiT or ZIKV LgBiT-NS2B and NS3pro-SmBiT. NanoLuc luciferase and cell viability was 155 
measured the following day and the percentage compared to DMSO treated cells was 156 
calculated. The benzimidazole-pyrrolones C1-C5 inhibited the RT-eEF1A interaction more 157 
strongly than the ZIKV NS2B-NS3pro interaction (Fig 2A-E). While compound C3 inhibited 158 
the RT-eEF1A interaction by 50% at 1 µM (IC50), it did not elicit dose-dependent inhibition at 159 
higher concentrations (Fig 2C), and this was similar for the structurally related C2 compound 160 
(Fig 2B). C1, C4 and C5 showed dose-dependent inhibition of the RT-eEF1A interaction from 161 
25 µM to 0.78 µM (Fig 2A, D and E). C4 (IC50 2 µM) and C5 (IC50 3 µM) had comparable 162 
inhibitor potency but cell viability was slightly greater for C5 (Fig 2E). The 50% cytotoxic 163 
concentration (CC50) was not reached for any of the compounds, however the reduction in cell 164 
viability at each concentration must be taken in to consideration when analysing the inhibition 165 
of RT-eEF1A interaction at each concentration. The results indicate that the benzimidazole-166 
pyrrolone compounds identified can specifically inhibit the HIV-1 RT-eEF1A interaction with 167 
varying potency. 168 
The oxazole-benzenesulfonamides C6, C7, C8 and C9 inhibited the HIV-1 RT-eEF1A 169 
interaction substantially more than the ZIKV NS2B-NS3pro control interaction, with cells still 170 
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being viable (Fig 3A-D). C6 had higher cytotoxicity and inhibition of the control ZIKV NS2B-171 
NS3pro interaction compared to C7, C8 and C9, and was not used further. C10 did not inhibit 172 
the RT-eEF1A interaction more than the ZIKV NS2B-NS3pro interaction and was therefore 173 
used as negative control (Fig 3E). C7 inhibited the RT-eEF1A interaction more effectively 174 
(IC50 0.35 µM) than the ZIKV NS2B-NS3pro interaction (IC50 17.5 µM) and the CC50 was not 175 
reached with the concentrations tested, however the cell viability was reduced by 176 
approximately 20% at the IC50 (Fig 3B). C8 was of comparable potency against RT-eEF1A 177 
(IC50 0.5 µM) to C7, and the cell viability was also reduced by approximately 20% at the IC50 178 
(Fig 3C). C9 was more cytotoxic than C7 and C8 at 0.195 µM and had an IC50 0.2 µM for the 179 
RT-eEF1A interaction and 12.5 µM for the ZIKV NS2B-NS3pro interaction. A non-linear 180 
inhibition curve was not fit with the data because the inhibition by C7, C8 and C9 did not 181 
represent a simple inhibition model, where inhibition was stronger at 0.39 µM than 0.78 µM 182 
and 1.56 µM for C7 (Fig 3B) and C9 (Fig 3D), and inhibition was stronger at 0.78 µM than 183 
1.56 µM and 3.125 µM for C8 (Fig 3C). The reason for this is unknown. However, inhibition 184 
was dose-dependent at a majority of concentrations. For all compounds except C6, the 185 
inhibition of the NanoBiT signal for the ZIKV NS2B-NS3pro interaction mostly matched the 186 
cell viability, indicating that inhibition of this interaction was due to cytotoxicity, while the 187 
increased inhibition of the HIV-1 RT-eEF1A was specific. Therefore, the oxazole-188 
benzenesulfonamides C7-C9 are identifiable inhibitors of the HIV-1 RT-eEF1A interaction. 189 
Next we investigated the effects of C7 –C10 in a single cycle of HIV-1 replication in the 190 
presence of the oxazole-benzenesulfonamides using a firefly luciferase reporter HIV-1. 191 
HEK293T cells were incubated with VSV-G pseudotyped HIV-1 in the presence of varying 192 
concentrations of C7-C10, and cells were lysed at 29 h post-infection (hpi) and luciferase 193 
expression in cell lysate was measured. C7, C8 and C9 dose-dependently inhibited luciferase 194 
expression in HEK293T cells (Fig 3B-D), while C10 had no antiviral effect (Fig 3E). The 195 
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inhibition of HIV-1 infection was comparable to the inhibition of the RT-eEF1A interaction in 196 
the NanoBiT assay. 197 
Oxazole-benzenesulfonamides bind HIV-1 RT but not eEF1A 198 
To determine if the compounds bind directly to either HIV-1 RT or eEF1A, biolayer 199 
interferometry (BLI) was used and biosensors were coated with the RTp66/p51 heterodimer 200 
(Fig 4) or eEF1A (Fig 5). RT was purified from E.coli as described previously (21), and 201 
eEF1A was purified from HEK293T cells (Fig 5A and 5B). The binding of the compounds to 202 
HIV-1 RT or eEF1A coated biosensors was measured by incubating with increasing 203 
concentrations of compounds on the Octet-Red system. A double-reference subtraction was 204 
performed where the response detected from the reference sensor (GST-His coated sensors for 205 
RT or Biocytin coated sensors for eEF1A) incubated in compounds, as well as the response 206 
detected from the target sensor (RT or eEF1A coated sensors) incubated in buffer only, were 207 
subtracted from the response for the target sensor incubated with compounds. There was no 208 
specific dose-dependent response for the RT sensor incubated in any of the benzimidazole-209 
pyrrolones (Fig 6A-E), and therefore these compounds were not characterised further. 210 
Delavirdine and all the oxazole-benzenesulfonamides (C6-C9) except the negative control 211 
(C10) showed dose-dependent binding to the RT coated probe (Fig 4, 6F and 6G). Under these 212 
conditions, the binding affinity (KD) calculated from the steady state analysis was 15 µM for 213 
C7 (Fig 4A, right), 29 µM for C8 (Fig 4B, right), 34 µM for C9 (Fig 4C, right), and 63 µM 214 
for delavirdine (Fig 4D, right). Specific and dose-dependent binding to an eEF1A biosensor 215 
was not detected for C7-C9 or delavirdine (Fig 5C-F). The data shows that the oxazole-216 
benzenesulfonamides C7-C9 were specific RT binding compounds with no affinity for eEF1A. 217 
Oxazole-benzenesulfonamides inhibit reverse transcription during infection but not in 218 
vitro enzymatic activity 219 
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To determine whether and which stages of the HIV-1 life cycle can be affected by the oxazole-220 
benzenesulfonamides, the optimal compound and virus concentration for inhibition in HeLa 221 
cells was determined to be used in a time-of-addition (TOA) assay. VSV-G pseudotyped HIV-222 
1 with an eGFP reporter in the Nef open reading frame (HIV-1NL4.3-∆nef-eGFP) was spinoculated 223 
with HeLa cells for 1.5 hrs at 16 °C, then unbound virus was removed and 0.39 µM or 0.78 µM 224 
of C7-9 were added and incubated for 24 hrs. These concentrations were used because they 225 
were the lowest concentration that produced 40-60% inhibition of HIV-1 infectivity in 226 
HEK293T cells (Fig 3B-D). HeLa cells were used for TOA assays due to their superior 227 
attachment during the infection, washing and compound addition stages, and maintained 228 
almost 100% cell viability apart from C9 at 0.78 µM which had 80% cell viability compared to 229 
DMSO treated cells (Fig 7A). Cells were fixed at 24 hpi and analysed by flow cytometry and 230 
percentage of infected cells was determined by eGFP expression. C7 and C8 had no inhibition 231 
at 0.39 µM, while C9 inhibited infection by 15%, however there was significant inhibition of 232 
percentage of infected cells at 0.78 µM for C7, C8 and C9 (Fig 7B) compared to DMSO 233 
treated cells (p < 0.05). C7, C8 and C9 also inhibited non-pseudotyped HIV-1 in TZMBL cells 234 
(Fig 8). The concentration of HIV-1 used in infection was titrated down, and C7-9 had 235 
increased inhibition in a virus tissue culture infectious dose 50 (TCID50) dependent manner, 236 
where C7 and C9 inhibited percentage infection by 3-fold, and C8 by 35% at the lowest HIV-1 237 
concentration (Fig 7C). Therefore, HeLa cells were infected with HIV-1 to achieve 238 
approximately 40% infection (0.8 TCID50) in DMSO treated conditions, and 0.78 µM of C7-9 239 
was added in hourly intervals up to 8 hpi, then at 10 hpi and 12 hpi. Nevirapine (5 µM) and 240 
raltegravir (1 µM) addition was included as controls of RT and integrase (IN) inhibition. The 241 
percentage of inhibitory activity of the compound compared to DMSO at each time-point was 242 
calculated so that the inhibitory activity of the compound was 100% when added at 0 hpi. 243 
Nevirapine still maintained 100% inhibitory activity when added up to 2 hpi, however the 244 
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inhibitory activity was sharply reduced when addition was delayed between 3-8 hpi (Fig 7D). 245 
Since nevirapine loses its antiviral activity once reverse transcription is complete, the data 246 
indicates that reverse transcription was completed by 8 hpi. Susceptibility of HIV to raltegravir 247 
was approximately 2 h later than nevirapine, and the data indicates that integration was 248 
completed by 10 hpi (Fig 7D). Delaying C7 addition to 8 hpi reduced the inhibitory activity of 249 
C7 by 50% (Fig 7D), indicating half of the antiviral activity of the compound is during 250 
uncoating and reverse transcription. However, C7 still maintained about 40% of its antiviral 251 
activity when added at 12 hpi, indicating unknown post-integration effects exist. C8 and C9 252 
displayed similar profiles to C7, however inhibitory activity remained for slightly longer after 253 
infection (Fig 7D). 254 
Since C7-9 bind RT, an in vitro RT activity assay was performed to determine if these 255 
compounds also inhibit the catalytic activity of RT in vitro. HIV-1 RT, homopolymer poly(A) 256 
DNA template and oligo(dT) primers were incubated in DMSO, nevirapine, delavirdine or the 257 
oxazole-benzenesulfonamides at 5 µM for 3 hrs and reverse transcription products were 258 
measured by a standard colorimetric ELISA. While nevirapine and delavirdine significantly 259 
inhibited reverse transcription, the oxazole-benzenesulfonamides did not affect the catalytic 260 
activity of RT in vitro (Fig 7E). However HIV-1 DNA products of viral reverse transcription 261 
in cells were measured in HeLa cell lysates by qPCR after 5 hpi. This showed that C7, C8 and 262 
C9 at 5 µM inhibited strong-stop DNA (Fig 7F) and late stage reverse transcription DNA 263 
products (Fig 7G) at 5 hpi. Together this indicates that C7, C8 and C9 did not directly inhibit 264 
HIV-1 RT enzymatic activity in vitro, but did inhibit reverse transcription in cells during 265 
infection through a different mechanism. 266 
Oxazole-benzenesulfonamides inhibit infectivity and replication in human primary 267 
activated CD4
+
 T cells 268 
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Human primary activated CD4
+
 T cells were infected with luciferase reporter HIV-1 in the 269 
presence of C7, C8 or C9 and lysed at 29 hpi, as described earlier for HEK293T cells. For C8 270 
and C9 there was no inhibition of HIV-1 at 0.195 µM, and approximately 20% more inhibition 271 
of luciferase signal from HIV-1 infection compared to cell viability measured by MTS assay at 272 
0.78 µM and 1.56 µM (Fig 9B and C). After 29 hrs of treatment with 0.39 µM C7 or C8, the 273 
cell viability was more than 90% and, while at this concentration C8 did not inhibit HIV-1 274 
infection (Fig 9B), C7 inhibited luciferase expression by 3-fold (p < 0.001 compared to cell 275 
viability) (Fig 9A). 276 
Since 0.39 µM C7 was the only concentration tested that significantly inhibited a single-round 277 
of HIV-1 infection in human primary activated CD4
+
 T cells, this concentration as well as 278 
0.293 µM or 0.195 µM was used to monitor HIV-1 replication over several days in CD4
+
 T 279 
cells.  The live-cell count as determined by trypan blue staining showed that there was a similar 280 
number of cells when treated with either DMSO (0.1%) or C7 at 0.39 µM for 1 day (Fig 9D), 281 
matching the MTS data (Fig 9A). However, the number of live cells was lower when treated 282 
with 0.39 µM C7 compared to the DMSO treated samples at 2, 4 and 6 dpi (Fig 9D), although 283 
there was only a statistically significant difference on day 4 (p < 0.01). Treatment of cells with 284 
0.39 µM C7 did not lead to an increase in the number of dead cells (Fig 9E), and cells 285 
maintained a round and translucent morphology similar to DMSO treated cells throughout the 286 
experiment (Fig 9F-I)). Treatment of cells with 0.293 µM or 0.195 µM did not affect the 287 
number of live or dead cells compared to DMSO treatment (Fig 9D and E). 288 
HIV-1 p24 in the cell culture supernatant was measured by ELISA on 0, 1, 2, 4 and 6 dpi. 289 
Human primary activated CD4
+
 T cells treated with 0.39 µM C7 had lower levels of p24 in the 290 
supernatant at every dpi measured, while treatment with 0.293 µM or 0.195 µM did not 291 
significantly inhibit p24 release into the supernatant (Fig 9J-M, top). When the ratio of 292 
picograms of p24 per cell was calculated, there was less p24 released into the supernatant per 293 
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cell when cells were treated with 0.39 µM C7 at each dpi (Fig 9J-M, bottom), however this 294 
was only statistically significant on 4 and 6 dpi (p < 0.05). This suggests that C7 can inhibit 295 
HIV-1 infection and replication in human primary CD4
+
 T cells at 0.39 µM.  296 
Oxazole-benzenesulfonamides inhibit infectivity NNRTI-resistant mutant HIV-1 in 297 
HEK293T cells 298 
To determine if the oxazole-benzenesulfonamides were able to inhibit HIV-1 mutants that are 299 
resistant to the NNRTIs nevirapine and delavirdine, luciferase reporter HIV-1 with drug 300 
resistance mutations K103N or Y181C in RT were used to infect HEK293T cells and 301 
compounds were added at the time of infection. Nevirapine and delavirdine strongly inhibited 302 
WT HIV-1 at concentrations between 0.098 µM and 1.56 µM, but nevirapine did not inhibit 303 
K103N or Y181C mutants at up to 0.39 µM, and 1.56 µM nevirapine only inhibited these 304 
mutant strains by 40% (Fig 10A and B). Delavirdine did not inhibit K103N HIV-1 at 0.098 305 
µM, and had reduced inhibition compared to WT HIV-1 at the concentrations tested. However, 306 
C7 and C8 inhibited K103N and Y181C RT mutant HIV-1 at levels similar to WT HIV-1 (Fig 307 
10C and D). This indicates that the oxazole-benzenesulfonamides can inhibit the K103N and 308 
Y181C mutant NNRTI-resistant strains of HIV-1. 309 
DISCUSSION 310 
We have previously demonstrated that the HIV-1 RT interaction with eEF1A is important for 311 
reverse transcription, uncoating and replication (19-21). Here we have identified a subset of 312 
oxazole-benzenesulfonamide compounds that inhibited the interaction between RT and eEF1A 313 
in a live-cell NanoBiT assay. The high-throughput NanoBiT screening assay has the advantage 314 
of immediately measuring cell viability in the same cells after measuring luciferase signal, and 315 
ensures that hits identified are bioavailable and tolerated by the cell at the first screen. By using 316 
a different protein-protein interaction as a control, such as the interaction between ZIKV NS2B 317 
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and NS3pro, the specificity of compound inhibition is confirmed early in the screening process, 318 
and the identification of inhibitors of a second interaction is possible. The inhibitors of the RT-319 
eEF1A interaction in NanoBiT assay, named C7, C8 and C9, specifically bound to HIV-1 RT 320 
and inhibited reverse transcription in HeLa cells and inhibited HIV-1 infection in HEK293T 321 
and HeLa cells, while C7 also inhibited replication in human primary CD4
+
 T cells. The 322 
oxazole-benzenesulfonamides also inhibited infection by common NNRTI-resistant HIV-1 323 
mutants and, since NNRTIs inhibit in vitro RT enzymatic activity while our compounds do not, 324 
our data suggests that these compounds may represent a new class of RT-binding anti-HIV-1 325 
inhibitors with a mechanism of action different to current NNRTIs. While the time-of-addition 326 
assays suggest that inhibition of HIV-1 by oxazole-benzenesulfonamides is complex, our data 327 
provides evidence that RT binding compounds (Figure 4) can inhibit RT interaction with 328 
eEF1A (Figure 3) and can  reduced viral DNA synthesis post-infection and reduced infectivity 329 
(Figure 5, 6 and S3). It is notable that cytosolic sulfotransferase family 1A member 1 330 
(SULT1A1) has been reported to be important during late stages of HIV-1 reverse transcription 331 
(27), and all oxazole-benzenesulfonamide series compounds are in the ChemDiv 332 
“sulfotransferase compound library”, but it is not known if these compounds have any anti-333 
sulfotransferase activity. 334 
Part of the inhibition of RT-eEF1A NanoBiT signal and HIV-1 luciferase signal in HEK293T 335 
cells is likely due to partial cytotoxicity, and it is unclear to what extent this partial cytotoxicity 336 
affects the IC50. The selectivity index of these compounds were not calculated since they did 337 
not reach a CC50 in HEK293T cells. The oxazole-benzenesulfonamides had increased toxicity 338 
at higher concentrations in CD4
+
 T cells compared to HEK293T cells; however toxicity was 339 
lower in CD4
+ 
T cells incubated with 0.39 µM of C7 and C8. C7 was at a high enough 340 
concentration (0.39 µM) to inhibit HIV-1 replication without adversely affecting cell viability 341 
in CD4
+
 T cells, while the higher concentrations of C8 and C9 required for antiviral activity in 342 
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CD4
+
 T cells had significant cytotoxicity. The selectivity index for a single round infection in 343 
human primary CD4
+
 T cells treated with C7 was 2.3, which was too low to perform extensive 344 
characterisation in these cells. The enhanced potency of C7 compared to C8 and C9 in CD4
+ 
T 345 
cells may reflect the increased binding affinity of C7 to RT in BLI assay. However, delavirdine 346 
binding affinity in our BLI assays was significantly higher than has been previously reported 347 
(28). This is likely due to assay-specific differences, including dissociation buffer and 348 
temperature, and therefore indicates the binding affinity of C7, C8 and C9 may be different in 349 
different assay conditions. However, the BLI assays were employed primarily to qualitatively 350 
determine compound binding to RT. 351 
The oxazole-benzenesulfonamides C6-C10 all share a common 4-(oxazol-5-352 
yl)benzenesulfonamide substructure, however they have variable chemical substituents at both 353 
ends. The most active compounds have a distinctly kinked shape that arises from their 354 
unsymmetrical tertiary sulfonamide compared to the linear symmetrical structure of the 355 
inactive compound C10. The secondary sulfonamide and associated H-bond donor NH group 356 
could be responsible for the lower binding affinity and antiviral potency of C9 in HEK293T 357 
cells which is partially recovered with the close analogue C8 that has an N-methyl group, 358 
however C9 was more potent than C8 in HeLa cells. The best compound C7 contains the 359 
tertiary sulfonamide constrained by an additional 5-membered ring that rigidifies the kinked 360 
structure that appears to be favoured for binding. In C6 the more acute angle conferred by the 361 
6-membered ring appears to have directed the aromatic ring to an unfavourable position or 362 
caused a steric clash. The 2-cyclopropyloxazole also appears to be tolerated. Although only a 363 
very small series of compounds has been evaluated here, it is likely that further structure-active 364 
relationships could be exploited to enhance the antiviral activity and reduce the toxicity of 365 
these oxazole-benzenesulfonamides in future studies. 366 
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Previous studies in our lab have comprehensively characterised the importance of eEF1A in 367 
interacting with the HIV-1 RT, and the eEF1A-binding drug didemnin B did not inhibit the 368 
interaction but did inhibit HIV-1 reverse transcription (20). This indicated that the RT-eEF1A 369 
complex was important for HIV-1 replication and a potentially druggable target. The oxazole-370 
benzenesulfonamides had a similar phenotype to RT containing the E300R mutation, which we 371 
previously reported did not inhibit RT enzymatic activity in an in vitro homopolymer DNA 372 
assay but did inhibit the RT interaction with eEF1A and impaired reverse transcription and 373 
replication in cells (21). 374 
There are reports of other compounds with a benzenesulfonamide substructure having anti-375 
HIV-1 activity. A “dihydrobenzo-1,4-dioxin-substituted analog of N-(3-aminoquinoxalin-2-376 
yl)-4-chlorobenzenesulfonamide” (DQBS) compound bound directly to HIV-1 Nef protein and 377 
inhibited Nef-dependent MHC class I downregulation and replication (29). The authors 378 
suggested that DQBS may inhibit Nef interaction with effector proteins required for Nef 379 
function. It is notable that Nef has also been shown to interact with eEF1A (30), but whether 380 
certain benzenesulfonamides affect this interaction is unknown. Another study found that 2,4-381 
difluoro-N-8-quinolinyl-benzenesulfonamide derivatives inhibit HIV-1 Rev function and HIV-382 
1 replication (31). The sulfonamide linker in this compound was not important for inhibition of 383 
Rev, but was important for the anti-HIV-1 activity of the compound (31), suggesting there may 384 
be another mechanism of HIV-1 inhibition other than anti-Rev activity. Kang et al. performed 385 
structure-based molecular hybridization and subsequent decorating to optimise thiophene[3,2-386 
d]pyrimidine derivatives based on crystal structures of NNRTIs and RT (32). They synthesised 387 
48 derivatives and the most potent compound contained a primary benzenesulfonamide group 388 
(4-PhSO2NH2) that made H-bonds with K104 and V106 in RT. An earlier study by Masuda et 389 
al. also found benzenesulfonamide derivatives with inhibitory activity against HIV-1 with WT 390 
or NNRTI-resistant mutant RT (33), while Pala et al. found benzenesulfonamide derivatives 391 
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that inhibited HIV-1 RT RNase H (34). Altogether, this suggests that benzenesulfonamide 392 
derived compounds may have more than one anti-HIV-1 activity and more than one anti-RT 393 
activity, and our data indicate that one of these activities is inhibiting the RT interaction with 394 
cellular eEF1A. 395 
In summary, we have identified new RT binding compounds that inhibit the HIV-1 RT 396 
interaction with eEF1A and inhibit HIV-1 replication. The oxazole-benzenesulfonamides 397 
identified here may represent a completely new class of anti-HIV-1 compounds as they bind 398 
RT but do not inhibit in vitro enzymatic activity. Resistance to anti-HIV-1 drugs is an 399 
increasing problem (9), and our potential new class of compounds inhibit common NNRTI-400 
resistant HIV-1 strains. It is also possible that if the oxazole-benzenesulfonamides bind at the 401 
interaction interface, then a resistance mutation that affects this interface may have a fitness 402 
cost that could inhibit HIV-1 replication and prevent emergence of resistant strains. However, 403 
the oxazole-benzenesulfonamides may be acting through an allosteric effect at an RT region 404 
where mutation may not impose a fitness cost. The potential for novel compounds to inhibit the 405 
interaction between a HIV-1 protein and a host cell protein has been demonstrated with the 406 
development of IN/LEGDF inhibitors, called LEDGINs, that are in pre-clinical trials (35). 407 
Structure determination of the HIV-1 RT-eEF1A complex by co-crystallisation or cryogenic 408 
electron microscopy (cryo-EM) could provide valuable information for drug design and 409 
compound optimisation. Hit-to-lead discovery of new compounds based on the structure of C7, 410 
C8 and C9 using medicinal chemistry, pharmacophore modelling and molecular docking 411 
studies may progress a compound to pre-clinical trials as a new type of antiretroviral agent. 412 
 413 
 414 
 415 
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MATERIALS AND METHODS 416 
Cell lines and virus culture 417 
HEK293T (ATCC) cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 418 
(GIBCO) supplemented with 10% heat inactivated Fetal Calf Serum (FCS), penicillin (100 419 
IU/ml) and streptomycin (100 µg/ml). Opti-MEM media supplemented with 10% heat 420 
inactivated FCS, penicillin (100 IU/ml) and streptomycin (100 µg/ml) and 1 mM HEPES was 421 
used for HEK293T cells in NanoBiT assay. HeLa (Clone CCL-2, ATCC) cells were 422 
maintained in RPMI 1640 supplemented with 10% heat inactivated FCS, penicillin (100 IU/ml) 423 
and streptomycin (100 µg/ml). 424 
Ficoll density centrifugation was used to purify peripheral blood mononuclear cells (PBMCs) 425 
from buffy coat supplied by the Australian Red Cross Blood Service. Magnetic isolation of 426 
CD4
+
 T cells was performed using the EasySep
TM
 Human CD4
+
 T Cell Isolation Kit as per the 427 
manufacturer’s instructions (STEMCELL Technologies). Purified CD4+ T cells were activated 428 
by culturing in plates coated with anti-human CD3 (clone HIT3a) and anti-human CD27 429 
antibodies (clone CD28.2) (BioLegend) in RPMI 1640 supplemented with 20% heat 430 
inactivated FCS, 2 ng/ml interleukin-2 (IL-2) (Miltenyi Biotec), penicillin (100 IU/ml) and 431 
streptomycin (100 µg/ml) for 2 days. All cells were incubated at 37°C in 5% CO2. 432 
Stocks of VSV-G pseudotyped HIV-1pNL4-3-∆nef-eGFP or HIV-1pNL4-3.Luc.R-E- with wild-type, 433 
K103N or Y181C mutant RT, or WT HIV-1pNL4-3- were generated by transfection of the 434 
proviral plasmid in to HEK293T cells with or without a VSV-G expression vector using X-435 
tremeGENE HP transfection reagent (Roche). Cell culture supernatants were collected 48 436 
hours post-transfection and filtered through a 0.45 µm filter and stored at -80 °C. HIV-1 CA in 437 
virus stocks and other viral samples were measured using a RETROtek HIV-1 CA antigen 438 
ELISA (Zaptometrix, USA) as per manufacturer instructions. 439 
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Plasmids 440 
The HIV-1 RTp66 was inserted into the NanoBiT pBiT1.1-C[TK/LgBiT] vector using the 441 
XhoI and EcoRI restriction sites to fuse the NanoBiT LgBiT subunit of NanoLuc luciferase to 442 
the C-terminus of HIV-1 RTp66. The ZIKV NS2B gene was inserted into the pBiT1.1-443 
N[TK/LgBiT] vector using the XhoI and EcoRI restriction sites to fuse the NanoBiT LgBiT 444 
subunit of NanoLuc luciferase to the N-terminus of ZIKV NS2B. A codon-optimised eEF1A 445 
gene, and the ZIKV NS3pro gene, were inserted into the pBiT2.1-C[TK/SmBiT] using the 446 
XhoI and EcoRI restriction sites to fuse the NanoBiT SmBiT subunit of NanoLuc luciferase to 447 
the C-terminus of eEF1A and ZIKV NS3pro respectively. Inverse PCR was used to insert a 448 
FLAG tag at the C-terminus of ZIKV LgBiT-NS2B and a HA tag at the N-terminus of 449 
NS3pro-SmBiT using Phusion polymerase (New England Biolabs) as per the manufacturer 450 
instructions. The HIV-1pNL4-3.Luc.R-E- plasmid was used as a template in inverse PCR using 451 
CloneAmp HiFi PCR premix (Takara Bio USA Inc) and primers with nucleotide changes to 452 
introduce the K103N or Y181C mutant in RT, and the mutations were confirmed by 453 
sequencing. 454 
Western blot and Nano-Glo HiBiT Blotting System 455 
HEK293T cells were transfected with RTp66-LgBiT, eEF1A-SmBiT, HaloTag-SmBiT, 456 
LgBiT-NS2B-FLAG or HA-NS3pro-SmBiT for 24 hrs and cells were lysed using Glo Lysis 457 
Buffer (Promega). Cell lysates were run on SDS-PAGE gels and protein was transferred to 458 
Immobilon-P PVDF Membrane (Merk) using the Trans-Blot SD Semi-Dry Transfer Cell (Bio-459 
Rad). Where indicated, western blots were probed with mouse anti-HIV-1 RT (Santa Crus 460 
Biotechnology), mouse anti-FLAG (Cell Signalling), rabbit anti-HA (Cell Signalling), or 461 
mouse anti-eEF1A (Santa Cruz Biotechnology). To detect the SmBiT proteins, the Nano-Glo 462 
HiBiT Blotting System (Promega) was performed as per manufacturer’s instructions. 463 
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Compounds 464 
During the screening process, compounds were supplied in assay-ready format from 465 
Compounds Australia, Griffith Institute for Drug Discovery (GRIDD), Eskitis Building N75, 466 
Griffith University, Brisbane Innovation Park, Don Young Road, Nathan QLD 4111. One 467 
compound from each of the 1219 scaffolds from the Open Collection Scaffolds library were 468 
selected at random and plated into wells of a 96 well white opaque plate (Costar) in 0.5 µl 469 
DMSO at 5 mM compound concentration by the Assay Ready Plate BioCel system using Echo 470 
liquid handling. Each scaffold contains 60 or less structure activity relationship (SAR) 471 
meaningful compounds selected by GRIDD and Queensland Facility of Advanced 472 
Bioinformatics (QFAB). Compound plating was completed 24-48 hrs before being used in the 473 
NanoBiT assay and were sealed and stored at room temperature under nitrogen. Once scaffolds 474 
of interest were identified using NanoBiT, all SAR-meaningful compounds within that scaffold 475 
were provided by Compounds Australia in the same assay-ready format. The following 476 
identified ‘hits’ were purchased from ChemDiv in powder form and dissolved in DMSO; 477 
compound ID D086-0046, D086-0114, D086-0148, D487-0468, D487-0490, G408-0087, 478 
G408-2173, G408-2184F, G408-2081 and G408-0073. These compounds were given ‘C series’ 479 
codes and are described further in Table 2. Delavirdine mesylate, nevirapine and raltegravir 480 
powder (Sigma-Aldrich) were dissolved in DMSO and diluted to the required concentrations. 481 
NanoBiT 482 
HEK293T cells were seeded in 10 cm tissue culture plates overnight to reach approximately 483 
95% confluency the following day, and 5 µg of each LgBiT and SmBiT NanoBiT plasmids 484 
were transfected using X-tremeGENE HP transfection reagent (Roche) and incubated for six 485 
hrs at 37 °C. HIV-1 RTp66-LgBiT was co-transfected with eEF1A-SmBiT, and ZIKV LgBiT-486 
NS2B was co-transfected with ZIKV NS3pro-SmBiT. After the 6 hrs transfection, cells were 487 
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trypsinised and 40000 was seeded into wells of 96 well plates containing a 0.5 µl droplet of 5 488 
mM compound or 0.5 µl of DMSO in 100 µl final volume of Opti-MEM media to dilute the 489 
compound to a final concentration of 25 µM. For the dose-response experiments, compounds 490 
were serially diluted in Opti-MEM (Gibco) media in the 96 well plate before cells were added. 491 
Transfected cells were incubated in compounds overnight. NanoBiT substrate was added to 492 
cells at a final dilution of 1:100 and incubated at room temperature for 5 minutes before the 493 
luminescence signal was measured using a Biotek Synergy H4 Multi Mode Plate Reader 494 
(Winooski, VT, USA) at approximately 24 hrs post-transfection. 495 
Purification of eEF1A from HEK293T cells 496 
Human eEF1A was purified from HEK293T cells using a slightly modified published protocol 497 
(36). Briefly, HEK293T cells were lysed in purification buffer (30 mM potassium phosphate 498 
pH 7.5, 1 mM MgCl2, 15% glycerol, 6 mM β-mercaptoethanol) supplemented with 1 mM 499 
phenylmethane sulfonyl fluoride (PMSF) using a Dounce homogenizer. After centrifugation at 500 
10000 × g for 30 min at 4 °C, the supernatant was loaded into a pre-equilibrated 4 ml HiTrap 501 
DEAE-column (GE Healthcare) and allowed to flow through. The DEAE-column was then 502 
washed using purification buffer. The unbound proteins were collected and loaded into pre-503 
equilibrated 1 ml HiTrap SP-column (GE Healthcare). The SP-column was washed using 504 
buffer A with increasing concentrations of KCl (50 mM, 100 mM and 150 mM) and purified 505 
protein was then eluted in buffer A containing 300 mM KCl. The elution was concentrated and 506 
dialyzed using Ultra-0.5 Centrifugal Filter Unit with Ultracel-3K membrane (Amicon). The 507 
concentrated protein was stored in dialysis buffer (5 mM NaH2PO4/ Na2HPO4 pH 7.5, 1 mM 508 
MgCl2, 25% glycerol) at -80°C. The concentration of eluted proteins was determined by 509 
Bradford Assay (Bio-Rad) and the purity of eEF1A was analyzed by 10% SDS-PAGE with 510 
coomassie blue staining and eEF1A was detected by western blot using a mouse anti-eEF1A 511 
antibody (Santa Cruz Biotechnology). 512 
 o
n
 M
ay 13, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
22 
 
Biolayer interferometry (BLI) 513 
Ni-NTA (NTA) biosensors (Pall ForteBio, CA, USA) were coated with recombinant 6 x His-514 
tagged HIV-1 RTp66/p51 heterodimer purified from E.coli as previously described (21). Super 515 
Streptavidin (SSA) biosensors (Pall ForteBio, CA, USA) were coated with eEF1A1 purified 516 
from HEK293T cells and biotinylated using EZ-Link-Sulfo-NHS-Biotin following the 517 
manufacturer’s instructions (Pierce Biotechnology, IL, USA). Sensors for background 518 
reference subtraction were coated in recombinant purified GST-His for Ni-NTA biosensors or 519 
Biocytin (Sigma-Aldrich) for SSA biosensors. Biosensors were incubated in a standard kinetic 520 
buffer (1 mM phosphate, 15 mM NaCl, 0.002% Tween-20 and 0.1 mg/ml gelatine) with 2.5% 521 
DMSO or 3.125 µM, 6.25 µM, 12.5 µM, 25 µM, 50 µM or 100 µM of compounds for 120 522 
seconds to allow association (ka), and then washed in a standard kinetic buffer for 120 seconds 523 
to allow dissociation (kd). A double-reference subtraction was performed by subtracting the 524 
response for GST-His or Biocytin coated sensors in compounds and HIV-1 RT or eEF1A 525 
coated sensors in buffer only. The experiment was performed at 30 °C. The curves were fitted 526 
using a 1:1 model, global curve fitting grouped by colour, and Rmax linked. The KD and r
2
 527 
were calculated from the Steady State Analysis of responses. 528 
Time-of-addition assay 529 
HeLa cells were seeded at 20000 per well in 96 well plates overnight. Cells were infected with 530 
equal amounts of VSV-G pseudotyped HIVNL4.3-∆nef-eGFP by spinoculation at 1200 × g for 531 
1.5 hrs at 16 °C so that approximately 30-50% of cells were infected at 24 hpi (TCID50 0.6-1). 532 
Virus medium was removed and cells washed once with PBS and warm media supplemented 533 
with DMSO, 0.78 µM of C7, C8 or C9, 5 µM nevirapine or 1 µM raltegravir (final DMSO is 534 
0.1% v/v) was added at the post-infection times indicated. Cells were incubated for 24 hrs and 535 
fixed in 1% paraformaldehyde, and eGFP expression was analysed by flow cytometry. eGFP 536 
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expression (% infection) was normalised to the percentage infection of the DMSO only 537 
addition sample at each time-point and percentage of inhibition was calculated at each 538 
concentration using the formula: 100 × [1 – (normalised % infected cells of sample – 539 
normalised % infected cells at highest concentration)/(100 – normalised % infected cells at 540 
highest concentration)]. 541 
In vitro RT enzymatic activity assay 542 
The effect of compounds on in vitro enzymatic activity of RT was determined by incubating 5 543 
µM of compounds with recombinant HIV-1 RT, poly(A):oligo(dT)15 template and primer for 544 
3 hrs. The colorimetric reverse transcriptase assay (Roche) was performed as per manufacturer 545 
instructions. 546 
Virus infection and luciferase assays 547 
HEK293T cells were seeded overnight in 12 well plates at 200000 cells per well. Media was 548 
replaced the following day with media containing the indicated concentration of compounds 549 
and 8 µg/ml polybrene and incubated for 1 hr at 37 °C. HIV-1pNL4-3.Luc.R-E- with WT, K103N or 550 
Y181C RT was added to the cells and incubated for 29 hrs before lysis in Glo Lysis Buffer 551 
(Promega). For analysis of reverse transcription DNA products at 5 hpi in the presence of 5 µM 552 
of C7, C8 or C9, qPCR was performed as previously described (21).  553 
For single-round infection assays in CD4
+ 
T cells, 300000 human primary activated CD4
+
 T 554 
cells were infected with equal amounts of VSV-G pseudotyped HIV-1pNL4-3.Luc.R-E- for 1 hr at 555 
18 °C and C7, C8 or C9 was added to a final concentration of 0.195, 0.39, 0.78, or 1.56 µM. 556 
Cells were incubated at 37 °C for 29 hrs and cell viability was determined by MTS assay and 557 
cells were lysed in Glo Lysis Buffer (Promega). The lysate was mixed with Firefly Luciferase 558 
Assay substrate (Promega) and luminescence was measured using a Biotek Synergy H4 Multi 559 
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Mode Plate Reader (Winooski, VT, USA) and were normalised to the DMSO only treatment 560 
control. 561 
For replication assays, human primary activated CD4
+
 T cells were infected with HIV-1pNL4-3 562 
for 1.5 hrs at 37 °C. Cells were washed four times in PBS and the day 0 supernatant sample 563 
was taken at the last wash. Cells were resuspended in media and split equally into wells of 24 564 
well plates initially, and when necessary cells were transferred to 12 or 6 well plates. Media 565 
was supplemented with DMSO (1:1000) or 0.195, 0.293 or 0.39 µM of C7. Fresh media 566 
containing C7 was added every 24 or 48 hrs when required. Cells were incubated at 37 °C and 567 
cells were counted and cell culture supernatant was collected at 1, 2, 4 and 6 dpi and p24 was 568 
measured by ELISA. 569 
Statistical analysis 570 
An unpaired Student t test was performed for data in Fig 1E and Fig 1F. An ordinary two-way 571 
ANOVA with multiple comparisons was performed in Fig 7B-C and Fig 9A-E. An ordinary 572 
one-way ANOVA with multiple comparisons comparing each column to DMSO was 573 
performed in Figure 6F-I. The statistical significance of differences between data is indicated 574 
as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 575 
ACKNOWLEDGEMENTS 576 
We thank Moana Simpson, Rebecca Lang, Vee Halilovic, Deborah Wessling, Heather Watts 577 
and Joshua Hatton from Compounds Australia at Griffith University for processing compound 578 
orders and plating compounds in assay-ready plates. Griffith University is a recipient of 579 
Queensland Government “Smart State Research Facilities Fund” funding, and Australian 580 
Government funding provided under the “Super Science Initiative” and financed from the 581 
Education Investment Fund. 582 
 o
n
 M
ay 13, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
25 
 
The HIV-1pNL4-3.Luc.R-E- plasmid was a gift from Prof. Nathaniel Landau. 583 
This research was supported by National Health and Medical Research Council project grant 584 
1080465. G.T. was supported by the NHMRC Senior Research Fellowship APP1117748. Z.W. 585 
was supported by a grant of Science and Technology Program - International Cooperation 586 
Program (2013ZYH193), Ningxia, China and a grant of Ningxia Key Research and 587 
Development Program (2018BEG03065), Ningxia, China. The funders had no role in the study 588 
design, data collection and interpretation, or the decision to submit the work for publication. 589 
D.H., D.L. and D.J.R. designed the study. D.J.R., D.L., Z.W., L.W., M.C. and M.L. performed 590 
the experiments. D.J.R., D.L., and DH analysed the data. D.J.R., D.L., R.C.R., D.P.F., and D.H 591 
wrote the manuscript. D.J.R., D.L., Z.W., R.C.R., D.P.F., J.H., G.T., S-A.P., and D.H. 592 
participated in discussions and interpretation of the results. 593 
COMPETING INTERESTS 594 
The authors declare no competing interests. 595 
REFERENCES 596 
1. UNAIDS. 2018. UNAIDS Data 2018. 597 
2. Arts EJ, Hazuda DJ. 2012. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 598 
2:a007161. 599 
3. Hoffmann C, Rockstroh JK, Kamps BS. 2007. HIV Medicine, 15 ed. Flying Publisher, Paris, 600 
Cagliari, Wuppertal. 601 
4. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner 602 
JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. 603 
1996. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international 604 
panel. International AIDS Society-USA. JAMA 276:146-154. 605 
5. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, Rickenbach M, Malinverni R, 606 
Vernazza P, Battegay M. 1997. Impact of new antiretroviral combination therapies in HIV 607 
infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 608 
315:1194-1199. 609 
6. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, 610 
Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human 611 
immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-612 
860. 613 
 o
n
 M
ay 13, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
26 
 
7. von Wyl V, Yerly S, Böni J, Shah C, Cellerai C, Klimkait T, Battegay M, Bernasconi E, Cavassini 614 
M, Furrer H, Hirschel B, Vernazza PL, Ledergerber B, Günthard HF, Swiss HIVCS. 2012. 615 
Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-Naive Individuals Starting 616 
Modern Therapy Combinations. Clin Infect Dis 54:131-140. 617 
8. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, 618 
Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD. 2008. Antiretroviral 619 
drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International 620 
AIDS Society-USA panel. Clin Infect Dis 47:266-285. 621 
9. Organization WH. 2017. HIV Drug Resistance Report 2017. 622 
10. Waheed AA, Tachedjian G. 2016. Why Do We Need New Drug Classes for HIV Treatment and 623 
Prevention? Curr Top Med Chem 16:1343-1349. 624 
11. Warren K, Warrilow D, Meredith L, Harrich D. 2009. Reverse Transcriptase and Cellular 625 
Factors: Regulators of HIV-1 Reverse Transcription. Viruses 1:873-894. 626 
12. Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes SH, Arnold E. 2009. 627 
Structure and Function of HIV-1 Reverse Transcriptase: Molecular Mechanisms of 628 
Polymerization and Inhibition. J Mol Biol 385:693-713. 629 
13. Sharaf NG, Poliner E, Slack RL, Christen MT, Byeon IJL, Parniak MA, Gronenborn AM, Ishima 630 
R. 2014. The p66 immature precursor of HIV‐1 reverse transcriptase. Proteins: Structure, 631 
Function, and Bioinformatics 82:2343-2352. 632 
14. Sluis-Cremer N, Arion D, Abram ME, Parniak MA. 2004. Proteolytic processing of an HIV-1 pol 633 
polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 634 
heterodimer formation. Int J Biochem Cell Biol 36:1836-1847. 635 
15. Sluis-Cremer N, Tachedjian G. 2008. Mechanisms of inhibition of HIV replication by non-636 
nucleoside reverse transcriptase inhibitors. Virus Res 134:147-156. 637 
16. Hooker CW, Harrich D. 2003. The first strand transfer reaction of HIV-1 reverse transcription is 638 
more efficient in infected cells than in cell-free natural endogenous reverse transcription 639 
reactions. J Clin Virol 26:229-238. 640 
17. Warrilow D, Meredith L, Davis A, Burrell C, Li P, Harrich D. 2008. Cell Factors Stimulate 641 
Human Immunodeficiency Virus Type 1 Reverse Transcription In Vitro. J Virol 82:1425-1437. 642 
18. Warrilow D, Warren K, Harrich D. 2010. Strand transfer and elongation of HIV-1 reverse 643 
transcription is facilitated by cell factors in vitro. PLoS One 5:e13229. 644 
19. Warren K, Wei T, Li D, Qin F, Warrilow D, Lin M-H, Sivakumaran H, Apolloni A, Abbott CM, 645 
Jones A, Anderson JL, Harrich D. 2012. Eukaryotic elongation factor 1 complex subunits are 646 
critical HIV-1 reverse transcription cofactors. Proc Natl Acad Sci U S A 109:9587-9592. 647 
20. Li D, Wei T, Rawle DJ, Qin F, Wang R, Soares DC, Jin H, Sivakumaran H, Lin M-H, Spann K, 648 
Abbott CM, Harrich D. 2015. Specific Interaction between eEF1A and HIV RT Is Critical for HIV-649 
1 Reverse Transcription and a Potential Anti-HIV Target. PLoS Pathog 11:e1005289. 650 
21. Rawle DJ, Li D, Swedberg JE, Wang L, Soares DC, Harrich D. 2018. HIV-1 Uncoating and 651 
Reverse Transcription Require eEF1A Binding to Surface-Exposed Acidic Residues of the 652 
Reverse Transcriptase Thumb Domain. MBio 9. 653 
22. Mittelman A, Chun HG, Puccio C, Coombe N, Lansen T, Ahmed T. 1999. Phase II clinical trial of 654 
didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma 655 
multiforme (NSC 325319). Invest New Drugs 17:179-182. 656 
23. Shin DM, Holoye PY, Forman A, Winn R, Perez-Soler R, Dakhil S, Rosenthal J, Raber MN, 657 
Hong WK. 1994. Phase II clinical trial of didemnin B in previously treated small cell lung 658 
cancer. Invest New Drugs 12:243-249. 659 
24. Azad T, Tashakor A, Hosseinkhani S. 2014. Split-luciferase complementary assay: applications, 660 
recent developments, and future perspectives. Anal Bioanal Chem 406:5541-5560. 661 
25. Li Z, Brecher M, Deng YQ, Zhang J, Sakamuru S, Liu B, Huang R, Koetzner CA, Allen CA, Jones 662 
SA, Chen H, Zhang NN, Tian M, Gao F, Lin Q, Banavali N, Zhou J, Boles N, Xia M, Kramer LD, 663 
 o
n
 M
ay 13, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
27 
 
Qin CF, Li H. 2017. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by 664 
targeting NS2B-NS3 interaction. Cell Res 27:1046-1064. 665 
26. Dixon AS, Schwinn MK, Hall MP, Zimmerman K, Otto P, Lubben TH, Butler BL, Binkowski BF, 666 
Machleidt T, Kirkland TA, Wood MG, Eggers CT, Encell LP, Wood KV. 2016. NanoLuc 667 
Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in 668 
Cells. ACS Chem Biol 11:400-408. 669 
27. Swann J, Murry J, Young JA. 2016. Cytosolic sulfotransferase 1A1 regulates HIV-1 minus-670 
strand DNA elongation in primary human monocyte-derived macrophages. Virol J 13:30. 671 
28. Geitmann M, Unge T, Danielson UH. 2006. Biosensor-based kinetic characterization of the 672 
interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors. J Med Chem 673 
49:2367-2374. 674 
29. Trible RP, Narute P, Emert-Sedlak LA, Alvarado JJ, Atkins K, Thomas L, Kodama T, Yanamala 675 
N, Korotchenko V, Day BW, Thomas G, Smithgall TE. 2013. Discovery of a diaminoquinoxaline 676 
benzenesulfonamide antagonist of HIV-1 Nef function using a yeast-based phenotypic screen. 677 
Retrovirology 10:135. 678 
30. Abbas W, Khan KA, Kumar A, Tripathy MK, Dichamp I, Keita M, Mahlknecht U, Rohr O, 679 
Herbein G. 2014. Blockade of BFA-mediated apoptosis in macrophages by the HIV-1 Nef 680 
protein. Cell Death Dis 5:e1080. 681 
31. Zhong F, Geng G, Chen B, Pan T, Li Q, Zhang H, Bai C. 2015. Identification of 682 
benzenesulfonamide quinoline derivatives as potent HIV-1 replication inhibitors targeting Rev 683 
protein. Org Biomol Chem 13:1792-1799. 684 
32. Kang D, Fang Z, Li Z, Huang B, Zhang H, Lu X, Xu H, Zhou Z, Ding X, Daelemans D, De Clercq E, 685 
Pannecouque C, Zhan P, Liu X. 2016. Design, Synthesis, and Evaluation of Thiophene[3,2-686 
d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with 687 
Significantly Improved Drug Resistance Profiles. J Med Chem 59:7991-8007. 688 
33. Masuda N, Yamamoto O, Fujii M, Ohgami T, Fujiyasu J, Kontani T, Moritomo A, Orita M, 689 
Kurihara H, Koga H, Kageyama S, Ohta M, Inoue H, Hatta T, Shintani M, Suzuki H, Sudo K, 690 
Shimizu Y, Kodama E, Matsuoka M, Fujiwara M, Yokota T, Shigeta S, Baba M. 2005. Studies 691 
of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: synthesis and structure-692 
activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives. 693 
Bioorg Med Chem 13:949-961. 694 
34. Pala N, Esposito F, Rogolino D, Carcelli M, Sanna V, Palomba M, Naesens L, Corona A, Grandi 695 
N, Tramontano E, Sechi M. 2016. Inhibitory Effect of 2,3,5,6-Tetrafluoro-4-[4-(aryl)-1H-1,2,3-696 
triazol-1-yl]benzenesulfonamide Derivatives on HIV Reverse Transcriptase Associated RNase H 697 
Activities. International Journal of Molecular Sciences 17:1371. 698 
35. Vranckx LS, Demeulemeester J, Saleh S, Boll A, Vansant G, Schrijvers R, Weydert C, Battivelli 699 
E, Verdin E, Cereseto A, Christ F, Gijsbers R, Debyser Z. 2016. LEDGIN-mediated Inhibition of 700 
Integrase–LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV. EBioMedicine 701 
8:248-264. 702 
36. Yaremchuk A, Shalak VF, Novosylna OV, Negrutskii BS, Crépin T, El’skaya AV, Tukalo M. 703 
2012. Purification, crystallization and preliminary X-ray crystallographic analysis of mammalian 704 
translation elongation factor eEF1A2. Acta Crystallographica Section F: Structural Biology and 705 
Crystallization Communications 68:295-297. 706 
FIGURE LEGENDS 707 
Fig 1. Establishment of NanoBiT assay to screen inhibitors of the HIV-1 RT-eEF1A 708 
interaction. Western blots of HEK293T cells lysate after 24 hrs of transfection with the 709 
indicated NanoBiT expression vectors using (A) anti-RT, (B) the HiBiT Blotting System, (C) 710 
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anti-HA or (D) anti-FLAG antibodies. Luminescent signal from NanoBiT assay in HEK293T 711 
cells expressing E) RTp66-LgBiT and eEF1A-SmBiT or RTp66-LgBiT and HaloTag-SmBiT, 712 
or F) ZIKV LgBiT-NS2B and NS3pro-SmBiT or LgBiT-NS2B and HaloTag-SmBiT. Data is 713 
the mean of 3 independent experiments and error bars represent standard error of the mean. 714 
****, P < 0.0001. 715 
Fig 2. NanoBiT assay for benzimidazole-pyrrolone series compounds. Compound structure 716 
and NanoBiT assay for HEK293T cells incubated in A) C1, B) C2, C) C3, D) C4, and E) C5. 717 
NanoBiT assay was performed with HIV-1 RTp66-LgBiT co-transfected with eEF1A-SmBiT 718 
(red line) alongside ZIKV LgBiT-NS2B co-transfected with NS3pro-SmBiT (blue line). After 719 
luciferase was measured in live cells, MTS assay was performed to measure cell viability 720 
(black line). Luciferase units from NanoBiT assay and cell viability from MTS assay measured 721 
at each compound concentration was normalised to cells incubated in DMSO only. Data is the 722 
mean of 3 independent experiments performed in duplicate and error bars represent standard 723 
error of the mean. 724 
Fig 3. NanoBiT assay for oxazole-benzenesulfonamide series compounds. Compound 725 
structure and NanoBiT assay for HEK293T cells incubated in A) C6, B) C7, C) C8, D) C9, and 726 
E) C10. NanoBiT assay was performed with HIV-1 RTp66-LgBiT co-transfected with eEF1A-727 
SmBiT (red line) alongside ZIKV LgBiT-NS2B co-transfected with NS3pro-SmBiT (blue 728 
line). After luciferase was measured in live cells, MTS assay was performed to measure cell 729 
viability (black line). Luciferase units from NanoBiT assay and cell viability from MTS assay 730 
measured at each compound concentration was normalised to cells incubated in DMSO only. 731 
NanoBiT data is the mean of 4 independent experiments performed in duplicate and error bars 732 
represent standard error of the mean. HEK293T were cells infected with HIV-1pNL4-3.Luc.R-E- and 733 
incubated with 0.1 – 10 µM of B) C7, C) C8, D) C9 or E) C10. Cells were lysed after 29 hrs 734 
and luciferase units (RLU) at each concentration was normalised to the DMSO only treatment 735 
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control (green line). Infection data is the mean of 2 independent experiments performed in 736 
duplicate and error bars represent standard error of the mean. 737 
Fig 4. Oxazole-benzenesulfonamide series compounds bind HIV-1 RT in biolayer 738 
interferometry assay. NiNTA biosensors coated in HIV-1 RTp51/p66 heterodimer purified 739 
from E.coli were incubated in 3.125 µM (dark blue), 6.25 µM (red), 12.5 µM (light blue), 25 740 
µM (green), 50 µM (yellow) and 100 µM (purple) of (A) C7, (B) C8, (C) C9 or (D) 741 
delavirdine. Data presented is the association and dissociation of the compounds with the RT 742 
coated probes after a double-reference subtraction of RT biosensors incubated in buffer only, 743 
as well as GST-His coated NiNTA biosensors incubated in compounds (left). The experiment 744 
was performed at least 3 times with similar results and a representative data set is shown. The 745 
KD and r
2
 shown was calculated from the steady state analysis of responses (right). 746 
Fig 5. Oxazole-benzenesulfonamide compounds had no detectable binding to purified 747 
eEF1A. Human eEF1A purified from HEK293T cells were run on an SDS-PAGE gel and 748 
analysed by A) coomassie staining and B) western blot using a mouse anti-eEF1A antibody. 749 
Superstrepdavadin biosensors coated in biotinylated eEF1A purified from E.coli were 750 
incubated in C) C7, D) C8, E) C9 or F) delavirdine at concentrations of at least 100 µM. Data 751 
presented is the response of the eEF1A coated probes incubated in compounds after a double-752 
reference subtraction of eEF1A biosensors incubated in buffer only, as well as Biocytin SSA 753 
biosensors incubated in compounds. The experiment was performed at least 2 times with 754 
similar results and a representative data set is shown. 755 
Fig 6. Benzimidazole-pyrrolone series compounds and C10 do not bind RT in biolayer 756 
interferometry. NiNTA biosensors coated in HIV-1 RTp51/p66 heterodimer purified from 757 
E.coli and were incubated in 3.125 µM (dark blue), 6.25 µM (red), 12.5 µM (light blue), 25 758 
µM (green), 50 µM (yellow) and 100 µM (purple) of A) C1, B) C2, C) C3, D) C4, E) C5 F) C6 759 
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or G) C10 as indicated. Data presented is the response of the RT coated probes incubated in 760 
compounds after a double-reference subtraction of RT biosensors incubated in buffer only, as 761 
well as GST-His coated NiNTA biosensors incubated in compounds. The experiment was 762 
performed at least 3 times with similar results. 763 
Fig 7. Oxazole-benzenesulfonamide series compounds inhibit HIV-1 reverse transcription 764 
in cells but not in vitro. A) Cell viability of HeLa cells incubated with 0.39 µM or 0.78 µM of 765 
C7, C8 or C9 for 24 hrs measured using MTS assay and normalised to cells incubated in 766 
DMSO only. B) Percentage of infected HeLa cells (eGFP) when incubated in DMSO or 0.39 767 
µM or 0.78 µM of C7, C8 or C9 from 0 hpi for 24 hrs. This was repeated at 0.78 µM C7, C8 or 768 
C9 using a range HIV-1 concentrations to achieve a titration of TCID50 (C). D) Time-of-769 
addition assay where HeLa cells were infected with HIV-1 by spinoculation at 16 °C to achieve 770 
a TCID50 of approximately 0.8. The cells were washed and media containing DMSO only, 771 
0.78 µM of C7, C8 or C9, 5 µM nevirapine, or 1 µM raltegravir were added at indicated times 772 
post-infection. Cells were fixed at 29 hpi and eGFP expression was measured by flow 773 
cytometry. Data was normalised to the percentage infection of the DMSO only sample and the 774 
percentage inhibition was calculated, and is the mean of 4 independent experiments performed 775 
in duplicate. E) The in vitro RT enzymatic activity when incubated with DMSO only or 5 µM 776 
nevirapine, delavirdine, C7, C8, C9 or C10. F) Strong-stop DNA copy number or G) late DNA 777 
copy number at 5 hpi in the presence of DMSO only, C7, C8, C9 or C10 as measured by 778 
qPCR. Data is the mean of (panel D and E), or representative of (A, B, C, F and G), at least 2 779 
independent experiments performed in duplicates and error bars represent standard error of the 780 
mean. *, P < 0.05; ***, P < 0.001; ****, P <0.0001. 781 
Fig 8. Inhibition of non-pseudotyped HIV-1 in TZMBL cells. TZMBL cells were 782 
spinoculated with non-pseudotyped HIV-1NL4.3-∆nef-eGFP at 1200 x g and 37 °C for 1.5 h. Cells 783 
were washed and replaced with media containing DMSO or 0.78 µM C7, C8 or C9 and 784 
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incubated for 24 h before fixation in 1% paraformaldehyde and flow cytometry for eGFP 785 
expression to determine percentage of infected cells. Data is the mean of duplicate samples and 786 
is representative of two independent experiments. 787 
Fig 9. Oxazole-benzenesulfonamide series compounds inhibit HIV-1 infection in human 788 
primary activated CD4
+
 T cells. Human primary activated CD4
+
 T cells infected with VSV-G 789 
pseudotyped HIV-1pNL4-3.Luc.R-E- and incubated with 0.195, 0.39, 0.78, or 1.56 µM of A) C7, B) 790 
C8 or C) C9. Cell viability was determined by MTS assay and cells were lysed after 29 hrs and 791 
luciferase units (RLU) at each concentration was normalised to the DMSO only treatment 792 
control. Data is the mean of 2 independent experiments performed in triplicates and error bars 793 
represent standard error of the mean. A non-linear semi-log inhibition curve was fit using 794 
GraphPad Prism software. For replication assays, human primary activated CD4
+
 T cells were 795 
infected with HIV-1pNL4-3 for 1.5 hrs at 37 °C and unbound virus was washed away. Cells were 796 
cultured in DMSO (1:1000) or 0.195, 0.293 or 0.39 µM C7 for 6 days and cell culture 797 
supernatant was collected and live (D) and dead (E) cells were counted using trypan blue 798 
staining. Light microscopy of CD4
+
 T cells treated with DMSO (F) or 0.39 µM C7 (G) at 2 dpi 799 
at 10x magnification, and DMSO (H) or 0.39 µM C7 (I) treated cells at 4 dpi at 20x 800 
magnification. Total HIV-1 CA (pg) was measured in cell culture supernatant (top) collected 801 
on days (J) 1, (K) 2, (L) 4 and (M) 6 post-infection using a p24 ELISA, and this was 802 
normalised to total live cells (bottom). Data for replication assays is the mean of 1 independent 803 
experiment performed in triplicates, and is representative of 2 independent experiments. Error 804 
bars represent standard error of the mean (SEM). *, P < 0.05; **, P < 0.01; ***, P < 0.001.  805 
Fig 10. Oxazole-benzenesulfonamide series compounds inhibit infection of NNRTI 806 
resistant HIV-1 in HEK293T cells. HIV-1pNL4-3.Luc.R-E- with WT RT or RT containing the 807 
K103N or Y181C mutations were used to infect HEK293T cells and incubated with 0.098, 808 
0.39, or 1.56 µM of, A) nevirapine, B) delavirdine, C) C7 or D) C8. Cells were lysed at 29 hpi 809 
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and luciferase units (RLU) at each concentration was normalised to the DMSO only treatment 810 
control. Data is the mean of 2 independent experiments performed in duplicates and error bars 811 
represent standard error of the mean. 812 
Table 1. Summary of compound library screen.  813 
 NUMBER OF 
COMPOUNDS 
NUMBER OF 
HITS 
HIT RATE NUMBER OF 
SELECTED 
HITS 
a 
Non-specific 
screen 
1226 320 26.1% 168 
b 
Specific screen 168 4 2.38%  4 
c 
Derivatives 
screen 
150 16 10.66% 16 
d
 Dose response 
screen 
16 9 56.25% 9 + 1 negative 
control 
a Non-specific screen hit criteria: >40% RT:eEF1A NanoBit inhibition and >70% cell viability. 814 
b Specific screen hit criteria: Same as primary screen criteria plus >50% inhibition of RT:eEF1A NanoBiT signal 815 
compared to a control interaction NanoBiT signal. 816 
c Derivatives screen hit criteria: Same as secondary hit screen criteria. 817 
d Dose response screen hit criteria: Dose dependent inhibition of the RT:eEF1A NanoBiT signal and less 818 
inhibition of the ZIKV NS2B:NS3pro NanoBiT signal. 819 
 820 
 821 
 822 
 823 
 824 
 825 
 826 
 827 
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Table 2. Details of hit compounds for further investigation. 828 
COMPOUND 
CODE 
CHEMDIV 
ID 
NUMBER 
COMPOUNDS 
AUSTRALIA 
ID NUMBER 
SCAFFOLD 
SERIES 
MOLECULAR 
WEIGHT 
LOG P 
C1 D086-0046 SN00785766 Benzimidazole-
pyrrolone 
320.35 3.1 
C2 D086-0114 SN00785768 Benzimidazole-
pyrrolone 
338.80 4.0 
C3 D086-0148 SN00785769 Benzimidazole-
pyrrolone 
304.35 3.4 
C4 D487-0468 SN00786708 Benzimidazole-
pyrrolone 
322.34 3.1 
C5 D487-0490 SN00786711 Benzimidazole-
pyrrolone 
334.38 2.9 
C6 G408-0087 SN00791985 Oxazole-
benzenesulfonamide 
354.43 4.9 
C7 G408-2173 SN00792040 Oxazole-
benzenesulfonamide 
380.47 5.5 
C8 G408-
2184F 
SN00792041 Oxazole-
benzenesulfonamide 
368.46 5.4 
C9 G408-2081 SN00792038 Oxazole-
benzenesulfonamide 
354.4 5.5 
C10 G408-0073 SN00791982 Oxazole-
benzenesulfonamide 
383.47 4.2 
 829 
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